Tufts University

Wellesley College

New England Medical Center Hospitals. Inc.

M.i.t.

Other

Massachusetts Institute of Technology

New England Medical Center

Center for Blood Research, Inc.

Mass. Inst. of Technology

New England Med. Center Hospitals

Andrew C Webb

Philip E Auron

Charles A Dinarello

Alexander Rich

Sheldon M Wolff

Lee Gehrke

Lanny J Rosenwasser

James Francis Webb

Kendall Hal Seymour

Jacob David Webb

Beverly A Blazar

Wayne R Waterman

Junichi Tsukada

Sheldon M Wolff, Deceased

A modular slide for use on a staircase includes at least a first slide module with an entry section having an entry surface defining a seat and a gripping surface substantially opposite the entry surface. The modular slide also has a ramp section with an elongated surface extending from the entry section towards a terminal end of the ramp section, an underside being configured to rest upon portions of the staircase, and two opposing sidewalls spanning both the ramp section and the entry section and having an upper edge defining a handrail. An identical second slide module is configured to overlap and integrate with an upper portion of the first slide module to form a continuous slide surface and a continuous handrail of an extended modular slide.

Modular slide apparatus and system

A novel immunoregulatory factor, designated IL-X, is described which has been isolated from Mycoplasma. The subject invention also concerns polynucleotides which encode IL-X. IL-X protein is a growth factor for EBV transformed human B lymphocytes and for murine helper T lymphocytes. Also taught are methods of raising antibodies to IL-X, and cloning of IL-X.

Polynucleotides encoding a mycoplasma protein involved in cell growth regulation

The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells. The subject invention further concerns antibodies that are immunoreactive with human IL-1.beta. proteins.

Biologically active fragments of IL-1.beta.

The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.

Recombinant DNA which codes for interleukin-1

A method for finding an agent which inhibits interaction between LIL-Stat protein and a nucleic acid having a LIL-Stat binding sequence is described. The LIL-Stat protein is contacted with the nucleic acid in the presence of an agent which inhibits or does not inhibit the interaction between the LIL-Stat protein and the nucleic acid. It is determined whether or not the agent inhibits this interaction. Also described are a method for treating an inflammatory response in a mammal, a therapeutic inhibitory agent suitable for treating or preventing an inflammatory response in a mammal, and DNA molecules having a DNA sequence encoding a binding site for the LIL-Stat protein.

LIL-Stat DNA binding sites and methods for identifying inhibitory

The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. The subject invention further concerns antibodies that are immunoreactive with human IL-1.beta. proteins. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.

Antibodies to IL-1.beta.

The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes-stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.

IL-1.beta.protein precursor

The subject invention concerns truncated human Il-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.

Human IL-1 cDNA sequences encoding biologically-active human IL-1

The subject invention concerns truncated human IL-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.

Truncated human IL-1 cDNA sequences which encode biologically-active

The invention is directed to an Arg-Serpin human plasminogen activator inhibitor designated PAI-2. This protein is prepared via recombinant DNA means. The invention also includes other serpins which can be made by amino acid substitutions or deletions in conserved regions of PAI-1 and PAI-2, as shown in FIG. 4. The proteins of the invention can be used to inhibit, or at least modulate, human plasminogen activator activity in a variety of physiological conditions, e.g., fibrinolysis, tumor metastasis, and tumor growth.

Growing community of inventors

Milton, MA, United States of America

Andrew C Webb